Zymeworks Inc. (ZYME) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Zymeworks reported revenue of $106.0M, up 38.9% from $76.3M the year before. Net income was -$81.1M (a -76.6% net margin), or -$1.08 per diluted share. Gross margin was -87.3% and operating margin was -87.3%. Operating activities generated -$33.0M of cash, leaving -$34.5M of free cash flow. At fiscal year end, Zymeworks held $346.5M in total assets against $78.0M in total liabilities, including $41.2M of cash and equivalents.
Open the full interactive Zymeworks financials → Quarterly statements, key ratios, valuation history and price charts.
Zymeworks Key Stats
| Share Price | $25.07 |
|---|---|
| Market Cap | $1.83B |
| Revenue YoY Growth | +38.9% |
| 52-Week Range | $16.46 – $31.05 |
| Shares Outstanding | 73.0 million (basic, 2026 Q2) |
Zymeworks Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $412.5M | $76.0M | $76.3M | $106.0M |
| Cost of Goods Sold | — | — | $213.4M | $198.5M |
| Gross Profit | — | — | -$137.1M | -$92.5M |
| Operating Income | $130.5M | -$138.1M | -$137.1M | -$92.5M |
| Pre-Tax Income | $135.2M | -$119.2M | -$116.6M | -$79.8M |
| Income Tax | $10.9M | -$568,000 | $6.1M | $1.4M |
| Net Income | $124.3M | -$118.7M | -$122.7M | -$81.1M |
| Diluted EPS | $1.90 | -$1.72 | -$1.62 | -$1.08 |
Zymeworks Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $27.6M | $2.5M | $2.4M | $4.6M |
| Net Income | -$19.6M | -$41.2M | -$44.2M | -$45.0M |
| Diluted EPS | -$0.26 | -$0.55 | -$0.59 | -$0.62 |
Zymeworks Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $400.9M | $157.6M | $66.1M | $41.2M |
| Current Assets | $544.7M | $412.9M | $300.5M | $248.8M |
| Total Assets | $648.7M | $580.9M | $463.1M | $346.5M |
| Current Liabilities | $95.6M | $55.8M | $88.3M | $42.3M |
| Total Liabilities | $155.8M | $116.1M | $124.3M | $78.0M |
| Shareholders' Equity | $493.0M | $464.8M | $338.8M | $268.5M |
Zymeworks Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | $144.1M | -$118.3M | -$110.0M | -$33.0M |
| Cash From Investing | -$53.8M | -$207.3M | $38.8M | $26.7M |
| Cash From Financing | $108.6M | $81.8M | -$20.5M | -$18.6M |
| Free Cash Flow | $136.0M | -$120.8M | -$112.0M | -$34.5M |
Figures from Zymeworks' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Zymeworks financials page for every line item.
Zymeworks Company Profile
| Ticker | ZYME |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Middletown, Delaware |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001937653 |
Frequently Asked Questions
What was Zymeworks' revenue in fiscal 2025?
Zymeworks (ZYME) reported revenue of $106.0M for fiscal 2025.
What is Zymeworks' annual revenue history?
Zymeworks' annual revenue by fiscal year: 2022: $412.5M; 2023: $76.0M; 2024: $76.3M; 2025: $106.0M.
What was Zymeworks' net income in fiscal 2025?
Zymeworks reported net income of -$81.1M for fiscal 2025.
What was Zymeworks' earnings per share (EPS) in fiscal 2025?
Zymeworks' diluted EPS was -$1.08 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Zymeworks generate in fiscal 2025?
Zymeworks generated -$34.5M of free cash flow in fiscal 2025.
What was Zymeworks' revenue last quarter?
In its most recent reported quarter (2026 Q2), Zymeworks reported revenue of $4.6M.
How many shares of Zymeworks are outstanding?
Zymeworks reported a weighted average of 73.0 million basic shares outstanding in 2026 Q2.
What is Zymeworks' market cap?
Based on its latest closing price, Zymeworks (ZYME) has a market capitalization of about $1.83B.
When does Zymeworks' fiscal year end?
Zymeworks' fiscal year end, as registered with the SEC, is December 31.
Where is Zymeworks headquartered?
Zymeworks lists its business address in Middletown, Delaware in its SEC filings.